Multi-institutional phase II randomized trial integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α 2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)

収録刊行物

• Melanoma Res

  Melanoma Res 9 503-509, 1999